CA Patent

CA3212370A1 — Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Assigned to Sana Biotechnology Inc · Expires 2022-09-09 · 4y expired

What this patent protects

Provided are methods and uses related to cardiomyocyte cell therapies involving the administration of immunosuppressive agents for reducing or preventing rejection of administered allogeneic cardiomyocytes. In some embodiments, the methods are for treating a subject with a heart …

USPTO Abstract

Provided are methods and uses related to cardiomyocyte cell therapies involving the administration of immunosuppressive agents for reducing or preventing rejection of administered allogeneic cardiomyocytes. In some embodiments, the methods are for treating a subject with a heart disease or condition in combination with a cardiomyocyte cell therapy.

Drugs covered by this patent

Patent Metadata

Patent number
CA3212370A1
Jurisdiction
CA
Classification
—
Expires
2022-09-09
Drug substance claim
No
Drug product claim
No
Assignee
Sana Biotechnology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.